

33. Chu UB, Ruoho AE. Biochemical pharmacology of the sigma-1 receptor. *Mol Pharmacol*. 2016;89:142–153.
34. Lee CH, Lu W, Michel JC, et al. NMDA receptor structures reveal subunit arrangement and pore architecture. *Nature*. 2014;511:191–197.
35. James ML, Shen B, Zavaleta CL, et al. New positron emission tomography (PET) radioligand for imaging sigma-1 receptors in living subjects. *J Med Chem*. 2012;55:8272–8282.
36. Shen B, James ML, Andrews L, et al. Further validation to support clinical translation of ¹⁸F-FTC-146 for imaging sigma-1 receptors. *EJNMMI Res*. 2015;5:49.
37. Fischer G, Mutel V, Trube G, et al. Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit: characterization in vitro. *J Pharmacol Exp Ther*. 1997;283:1285–1292.
38. Zhou ZL, Cai SX, Whittemore ER, et al. 4-hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. *J Med Chem*. 1999;42:2993–3000.
39. Lever JR, Gustafson JL, Xu R, Allmon RL, Lever SZ. Sigma1 and sigma2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. *Synapse*. 2006;59:350–358.
40. McCracken KA, Bowen WD, de Costa BR, Matsumoto RR. Two novel σ receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity. *Eur J Pharmacol*. 1999;370:225–232.
41. Berardi F, Ferorelli S, Colabufo NA, Leopoldo M, Perrone R, Tortorella V. A multi-receptorial binding reinvestigation on an extended class of sigma ligands: N-[omega-(indan-1-yl and tetralin-1-yl)alkyl] derivatives of 3,3-dimethylpiperidine reveal high affinities towards sigma1 and EBP sites. *Bioorg Med Chem*. 2001;9:1325–1335.
42. Li Y, Wang X, Zhang J, et al. Synthesis and evaluation of novel ¹⁸F-labeled spirocyclic piperidine derivatives as sigma1 receptor ligands for positron emission tomography imaging. *J Med Chem*. 2013;56:3478–3491.
43. Liu X, Banister SD, Christie MJ, et al. Trishomocubanes: novel sigma ligands modulate cocaine-induced behavioural effects. *Eur J Pharmacol*. 2007;555:37–42.
44. Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S. Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. *Eur J Pharmacol*. 1996;306:271–279.
45. Kawamura K, Ishiwata K, Tajima H, et al. In vivo evaluation of ¹¹C-SA4503 as a PET ligand for mapping CNS sigma(1) receptors. *Nucl Med Biol*. 2000;27:255–261.
46. Cagnotto A, Bastone A, Mennini T. ³H-(+)-pentazocine binding to rat brain sigma 1 receptors. *Eur J Pharmacol*. 1994;266:131–138.
47. Prezzavento O, Campisi A, Ronsisvalle S, et al. Novel sigma receptor ligands: synthesis and biological profile. *J Med Chem*. 2007;50:951–961.
48. Maurice T, Su TP, Parish DW, Nabeshima T, Privat A. PRE-084, a sigma selective PCP derivative, attenuates MK-801-induced impairment of learning in mice. *Pharmacol Biochem Behav*. 1994;49:859–869.
49. Su TP, Wu XZ, Cone EJ, et al. Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand. *J Pharmacol Exp Ther*. 1991;259:543–550.
50. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. Sigma receptors: biology and function. *Pharmacol Rev*. 1990;42:355–402.

Erratum

In the article “Patient Travel Concerns After Treatment with ¹⁷⁷Lu-DOTATATE,” by Kendi et al. (*J Nucl Med*. 2020;61:496–497), the following sentence mistakenly provides an incorrect time frame, and reference 2 is unnecessarily cited. The original sentence reads “It is important to counsel patients in detail about the possibility of radiation detection when traveling in the first 6 wk after each therapy cycle (2).” The amended sentence should read “It is important to counsel patients in detail about the possibility of radiation detection when traveling after each therapy cycle.” The authors regret the error.